Patents by Inventor Tino PLEINER

Tino PLEINER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IgG NANOBODIES
    Publication number: 20240018267
    Abstract: The present invention relates to novel anti-IgG nanobodies, particularly nanobodies directed against rabbit or mouse IgG. Further, the invention relates to the use of said nanobodies and methods for producing them.
    Type: Application
    Filed: October 11, 2018
    Publication date: January 18, 2024
    Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Dirk GÖRLICH, Tino PLEINER
  • THERAPEUTIC AND DIAGNOSTIC VHH ANTIBODIES AGAINST SARS-COV-2 AND METHODS FOR THEIR ENHANCEMENT
    Publication number: 20230303664
    Abstract: The present invention pertains in the fields of antibody technology, protein engineering, medicine, pharmacology, infection biology, virology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that prevent cell entry of and infection by SARS-CoV-2, a strategy for an enhanced block of the homotrimeric viral spike proteins by symmetry-matching VHH-fusions, implementations of this strategy, as well as VHH antibodies for sensitive detection of SARS-CoV2-infections.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 28, 2023
    Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Dirk GÖRLICH, Volker CORDES, Thomas GÜTTLER, Philip GUNKEL, Renate REES, Jens KRULL, Kathrin GREGOR, Waltraud TAXER, Leonie NEUMANN, Tino PLEINER, Bianka MUSSIL, Ulrike TEICHMANN, Aksu METIN, Oleh RYMARENKO, Jürgen SCHÜNEMANN, Matthias DOBBELSTEIN, Kim Maren STEGMANN, Antje DICKMANNS
  • THERAPEUTIC AND DIAGNOSTIC VHH ANTIBODIES AGAINST SARS-COV-2 AND METHODS FOR THEIR ENHANCEMENT
    Publication number: 20230287087
    Abstract: The present invention pertains in the fields of antibody technology, protein engineering, medicine, pharmacology, infection biology, virology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that prevent cell entry of and infection by SARS-CoV-2, a strategy for an enhanced block of the homotrimeric viral spike proteins by symmetry-matching VHH-fusions, implementations of this strategy, as well as VHH antibodies for sensitive detection of SARS-CoV2-infections.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 14, 2023
    Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Dirk GÖRLICH, Volker CORDES, Thomas GÜTTLER, Philip GUNKEL, Renate REES, Jens KRULL, Kathrin GREGOR, Waltraud TAXER, Leonie NEUMANN, Tino PLEINER, Bianka MUSSIL, Ulrike TEICHMANN, Aksu METIN, Oleh RYMARENKO, Jürgen SCHÜNEMANN, Matthias DOBBELSTEIN, Kim Maren STEGMANN, Antje DICKMANNS